Investigational Drug Information for apabetalone
✉ Email this page to a colleague
What is the development status for investigational drug apabetalone?
apabetalone is an investigational drug.
There have been 8 clinical trials for apabetalone.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2015.
The most common disease conditions in clinical trials are Coronary Disease, Coronary Artery Disease, and Pulmonary Arterial Hypertension. The leading clinical trial sponsors are Resverlogix Corp, ICON plc, and Medidata Solutions.
There are thirty US patents protecting this investigational drug and three hundred and twelve international patents.
Summary for apabetalone
| US Patents | 30 |
| International Patents | 312 |
| US Patent Applications | 135 |
| WIPO Patent Applications | 95 |
| Japanese Patent Applications | 19 |
| Clinical Trial Progress | Phase 3 (2015-11-01) |
| Vendors | 60 |
Recent Clinical Trials for apabetalone
| Title | Sponsor | Phase |
|---|---|---|
| Apabetalone for Pulmonary Arterial Hypertension | Canadian Institutes of Health Research (CIHR) | Phase 2 |
| Apabetalone for Pulmonary Arterial Hypertension | Resverlogix Corp | Phase 2 |
| Apabetalone for Pulmonary Arterial Hypertension | Institut universitaire de cardiologie et de pneumologie de Québec, University Laval | Phase 2 |
Clinical Trial Summary for apabetalone
Top disease conditions for apabetalone
Top clinical trial sponsors for apabetalone
US Patents for apabetalone
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| apabetalone | ⤷ Sign Up | Pharmaceutical compositions for substituted quinazolinones | Resverlogix Corp. (Calgary, Alberta, CA) | ⤷ Sign Up |
| apabetalone | ⤷ Sign Up | Compositions and therapeutic methods for the treatment of complement-associated diseases | Resverlogix Corp. (Calgary, Alberta, CA) | ⤷ Sign Up |
| apabetalone | ⤷ Sign Up | Anti-inflammatory agents | Resverlogix Corp. (Calgary, Alberta, CA) | ⤷ Sign Up |
| apabetalone | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| apabetalone | ⤷ Sign Up | Therapy for promoting cell growth | MOLEAC PTE. LTD. (Singapore, SG) | ⤷ Sign Up |
| apabetalone | ⤷ Sign Up | Chemokine receptor modulators and uses thereof | FLX BIO, INC. (South San Francisco, CA) | ⤷ Sign Up |
| apabetalone | ⤷ Sign Up | 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (Ann Arbor, MI) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for apabetalone
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| apabetalone | Australia | AU2012330885 | 2031-11-01 | ⤷ Sign Up |
| apabetalone | Canada | CA2851996 | 2031-11-01 | ⤷ Sign Up |
| apabetalone | China | CN103945848 | 2031-11-01 | ⤷ Sign Up |
| apabetalone | Denmark | DK2773354 | 2031-11-01 | ⤷ Sign Up |
| apabetalone | European Patent Office | EP2773354 | 2031-11-01 | ⤷ Sign Up |
| apabetalone | Spain | ES2745471 | 2031-11-01 | ⤷ Sign Up |
| apabetalone | Hong Kong | HK1201751 | 2031-11-01 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
